| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1292 | 946 | 316 |
| Full Text Views | 18 | 3 | 0 |
| PDF Downloads | 18 | 3 | 0 |
Safety and Immunogenicity of a Plasmodium vivax Sporozoite Vaccine
Daniel M. Gordon
Daniel M. Gordon
Walter Reed Army Institute of Research, United States Army Medical Institute of Infectious Diseases, SmithKline Beecham Pharmaceuticals, Biomedical Research Institute, Washington, DC
Search for other papers by Daniel M. Gordon in
Current site
Google Scholar
PubMed
Search for other papers by Daniel M. Gordon in
Current site
Google Scholar
PubMed
Thomas M. Cosgriff
Thomas M. Cosgriff
Walter Reed Army Institute of Research, United States Army Medical Institute of Infectious Diseases, SmithKline Beecham Pharmaceuticals, Biomedical Research Institute, Washington, DC
Search for other papers by Thomas M. Cosgriff in
Current site
Google Scholar
PubMed
Search for other papers by Thomas M. Cosgriff in
Current site
Google Scholar
PubMed
Imogene Schneider
Imogene Schneider
Walter Reed Army Institute of Research, United States Army Medical Institute of Infectious Diseases, SmithKline Beecham Pharmaceuticals, Biomedical Research Institute, Washington, DC
Search for other papers by Imogene Schneider in
Current site
Google Scholar
PubMed
Search for other papers by Imogene Schneider in
Current site
Google Scholar
PubMed
Gail F. Wasserman
Gail F. Wasserman
Walter Reed Army Institute of Research, United States Army Medical Institute of Infectious Diseases, SmithKline Beecham Pharmaceuticals, Biomedical Research Institute, Washington, DC
Search for other papers by Gail F. Wasserman in
Current site
Google Scholar
PubMed
Search for other papers by Gail F. Wasserman in
Current site
Google Scholar
PubMed
William R. Majarian
William R. Majarian
Walter Reed Army Institute of Research, United States Army Medical Institute of Infectious Diseases, SmithKline Beecham Pharmaceuticals, Biomedical Research Institute, Washington, DC
Search for other papers by William R. Majarian in
Current site
Google Scholar
PubMed
Search for other papers by William R. Majarian in
Current site
Google Scholar
PubMed
Michael R. Hollingdale
Michael R. Hollingdale
Walter Reed Army Institute of Research, United States Army Medical Institute of Infectious Diseases, SmithKline Beecham Pharmaceuticals, Biomedical Research Institute, Washington, DC
Search for other papers by Michael R. Hollingdale in
Current site
Google Scholar
PubMed
Search for other papers by Michael R. Hollingdale in
Current site
Google Scholar
PubMed
Jeffrey D. Chulay
Jeffrey D. Chulay
Walter Reed Army Institute of Research, United States Army Medical Institute of Infectious Diseases, SmithKline Beecham Pharmaceuticals, Biomedical Research Institute, Washington, DC
Search for other papers by Jeffrey D. Chulay in
Current site
Google Scholar
PubMed
Search for other papers by Jeffrey D. Chulay in
Current site
Google Scholar
PubMed
A recombinant DNA Plasmodium vivax sporozoite vaccine containing the repeating region of the Salvador I strain circumsporozoite (CS) protein was produced in Escherichia coli. This vaccine was tested in 13 naive volunteers at doses of 10–1,000 µg. No serious adverse reactions were noted. None of 4 volunteers receiving the 10 µg dose developed antibodies measurable by ELISA. Six of 9 volunteers in the other dose groups developed measurable antibodies: 5 of 5 volunteers receiving 100 µg and 1 of 4 receiving 1,000 µg. Antibody responses measured by immunofluorescence assays paralleled those seen by ELISA. None of the volunteers developed antisera that inhibited sporozoite invasion of human hepatoma cells in vitro. Lack of a classical anamnestic response and lack of a typical dose response to increasing amounts of antigen suggests the possible presence of an immunosuppressive epitope in the repetitive region of the CS protein.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1292 | 946 | 316 |
| Full Text Views | 18 | 3 | 0 |
| PDF Downloads | 18 | 3 | 0 |